Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Ribera JM
- Morgades M
- Ciudad J
- Esteve J
- Genesca E
- Barba P
- Ribera J
- García Cadenas I
- Moreno MJ
- Martínez-Carballeira D
- Torrent A
- Martínez-Sánchez P
- Monsalvo S
- Gil C
- Tormo M
- Artola MT
- Cervera M
- González-Campos J
- Rodríguez-Medina C
- Bermúdez A
- Novo A
- Soria B
- Coll R
- Amigo ML
- López A
- Fernández Martín R
- Serrano J
- Mercadal S
- Cladera A
- Giménez-Conca AD
- Peñarrubia MJ
- Abella E
- Vall-Llovera F
- Hernández-Rivas JM
- Garcia A
- Bergua Burgues JM
- de Rueda B
- Sánchez-Sánchez MJ
- Serrano A
- Calbacho M
- Alonso Vence N
- Méndez-Sánchez JÁ
- García-Boyero R
- Olivares M
- Barrena S
- Zamora L
- Granada I
- Lhermitte L
- Feliu E
- Orfao A
Grupos
Abstract
The need for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL) with high-risk (HR) features and adequate measurable residual disease (MRD) clearance remains unclear. The aim of the ALL-HR-11 trial was to evaluate the outcomes of HR Ph-neg adult ALL patients following chemotherapy or allo-HSCT administered based on end-induction and consolidation MRD levels. Patients aged 15-60 years (y) with HR-ALL in complete response (CR) and MRD levels (centrally assessed by 8-color flow cytometry) <0.1% after induction and <0.01% after early consolidation, were assigned to receive delayed consolidation and maintenance therapy up to 2y in CR. The remaining patients were allocated to allo-HSCT. CR was attained in 315/348 patients (91%), with MRD <0.1% after induction in 220/289 patients (76%). By intention-to treat, 218 patients were assigned to chemotherapy and 106 to allo-HSCT. The 5-year (±95%CI) cumulative incidence of relapse (CIR), overall survival (OS) and event-free survival (EFS) probabilities for the whole series were 43%±7%, 49%±7% and 40±6%, respectively, with CIR and OS rates of 45±8% and 59±9% for patients assigned to chemotherapy and of 40±12% and 38±11% for those assigned to allo-HSCT, respectively. Our results show that avoiding allo-HSCT does not hamper the outcomes of HR Ph-neg adult ALL patients up to 60y with adequate MRD response after induction and consolidation. Better post-remission alternative therapies are especially needed for patients with poor MRD clearance. ClinicalTrials.gov (NCT01540812).
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Article
- Páginas:
- 1879-1894
- PubMed:
- 33150388
- Factor de Impacto:
- 5,515 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Citas Recibidas en Web of Science: 75
Documentos
- No hay documentos
Filiaciones
Keywords
- MINIMAL RESIDUAL DISEASE; FLOW-CYTOMETRY; BLINATUMOMAB; THERAPY; MRD
Campos de Estudio
Cita
Ribera JM,Morgades M,Ciudad J,MONTESINOS P,Esteve J,Genesca E,Barba P,Ribera J,García I,Moreno MJ,Martínez D,Torrent A,Martínez P,Monsalvo S,Gil C,Tormo M,Artola MT,Cervera M,González J,Rodríguez C,Bermúdez A,Novo A,Soria B,Coll R,Amigo ML,López A,Fernández R,Serrano J,Mercadal S,Cladera A,Giménez AD,Peñarrubia MJ,Abella E,Vall F,Hernández JM,Garcia A,Bergua JM,de Rueda B,Sánchez MJ,Serrano A,Calbacho M,Alonso N,Méndez JÁ,García R,Olivares M,Barrena S,Zamora L,Granada I,Lhermitte L,Feliu E,Orfao A. Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia. Blood. 2020. 137. (14):p. 1879-1894. IF:23,629. (1).
Portal de investigación